# Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial

> **NCT05135546** · PHASE2,PHASE3 · TERMINATED · sponsor: **Supergene, LLC** · enrollment: 4 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Recombinant nonimmunogenic staphylokinase
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05135546
- **Lead sponsor:** Supergene, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-27
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-05-31
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** No patients
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05135546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05135546, "Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05135546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*